Is MKGAF.PK a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

98 people get MKGAF.PK articles and Market Currents by email alert.

Get email alerts on MKGAF.PK »

HEADLINES:

Merck's Management Discusses Q1 2013 Results - Earnings Call Transcript
Tue, May 14
Threshold Pharmaceuticals: TH-302 Phase IIb Clinical Results In First-Line Pancreatic Cancer
LifeSci Advisors • Fri, Apr 27, 2012 • 22 Comments
Which Q1 Biotech Movers Can Build Off Momentum?
Brian Nichols • Thu, Apr 12, 2012 • 3 Comments
Cancer Vaccine Approaches: A Race For Dominance In The Field
Andrew J. Norris • Mon, Apr 2, 2012 • 7 Comments
Weekly Stock Watch: March 12-16
VFC's Stock House • Tue, Mar 13, 2012 • 5 Comments
Oncothyreon And Lpath: Shares Collapsed, Primed For A Rebound?
VFC's Stock House • Fri, Mar 9, 2012 • 4 Comments
Immunotherapy Cancer Trials With Key Data Due In 2012
Chemistfrog • Wed, Jan 25, 2012 • 20 Comments
2012 Preview: Cancer Immunotherapy Catalysts
Michael Becker • Thu, Dec 15, 2011 • 20 Comments
Investors Digest BioCryst's New Data
M. E. Garza • Wed, Nov 9, 2011 • 1 Comment
Merck's Curious MS Acquisition Was A Gamble Worth Taking
EP Vantage • Tue, Sep 20, 2011 • 2 Comments
China Biotech Week In Review: Avenue Capital Starts $313 Million Fund For China Medical City
ChinaBio Today • Mon, Sep 19, 2011
Oncothyreon: Possible Pharma Blockbuster
Seth Shaw • Wed, Jul 20, 2011 • 21 Comments
Hunting for the Next Dendreon
Michael J. Ray • Mon, Jul 11, 2011 • 9 Comments
It May Be Time to Throttle Back on Oncothyreon
VFC's Stock House • Mon, Jun 27, 2011 • 3 Comments
Merck KGaA Leaves Multiple Sclerosis Field Wide Open for Novartis
Derek Lowe • Fri, Jun 24, 2011

To learn more about Seeking Alpha Pro, click here.

Merck's Curious MS Acquisition Was A Gamble Worth Taking
EP Vantage • Tue, Sep 20, 2011 • 2 Comments

Threshold Pharmaceuticals: TH-302 Phase IIb Clinical Results In First-Line Pancreatic Cancer
LifeSci Advisors • Fri, Apr 27, 2012 • 22 Comments
Which Q1 Biotech Movers Can Build Off Momentum?
Brian Nichols • Thu, Apr 12, 2012 • 3 Comments
Cancer Vaccine Approaches: A Race For Dominance In The Field
Andrew J. Norris • Mon, Apr 2, 2012 • 7 Comments
Weekly Stock Watch: March 12-16
VFC's Stock House • Tue, Mar 13, 2012 • 5 Comments
Oncothyreon And Lpath: Shares Collapsed, Primed For A Rebound?
VFC's Stock House • Fri, Mar 9, 2012 • 4 Comments
Immunotherapy Cancer Trials With Key Data Due In 2012
Chemistfrog • Wed, Jan 25, 2012 • 20 Comments
2012 Preview: Cancer Immunotherapy Catalysts
Michael Becker • Thu, Dec 15, 2011 • 20 Comments
Investors Digest BioCryst's New Data
M. E. Garza • Wed, Nov 9, 2011 • 1 Comment
China Biotech Week In Review: Avenue Capital Starts $313 Million Fund For China Medical City
ChinaBio Today • Mon, Sep 19, 2011
Oncothyreon: Possible Pharma Blockbuster
Seth Shaw • Wed, Jul 20, 2011 • 21 Comments
Hunting for the Next Dendreon
Michael J. Ray • Mon, Jul 11, 2011 • 9 Comments
It May Be Time to Throttle Back on Oncothyreon
VFC's Stock House • Mon, Jun 27, 2011 • 3 Comments
Merck KGaA Leaves Multiple Sclerosis Field Wide Open for Novartis
Derek Lowe • Fri, Jun 24, 2011

Merck's Management Discusses Q1 2013 Results - Earnings Call Transcript
Tue, May 14

There are no News articles on MKGAF.PK.

MKGAF.PK vs. ETF Alternatives

Company Description

Currently, there's no company description for MKGAF.PK.

Sector: Healthcare

Industry: Drug Related Products

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, December 19, 2012, 8:39 AM Stimuvax, a lung cancer vaccine that Germany's Merck (MKGAF.PK) has licensed from Oncothyreon (ONTY), failed to improve overall survival in a Phase III study. However, "notable treatment effects were observed in certain subgroups of patients." That's not enough to convince analysts: "Despite potential positive effects in subgroups, we consider the drug dead," says Deutsche Bank. Oncothyreon collapses 61%, while Merck is -2.9% in Frankfurt. (PR) Comment! [On the Move, Healthcare]
Tuesday, October 16, 2012, 9:01 AM Threshold Pharmaceuticals (THLD) jumps 13.5% after the FDA reaches an agreement for the Phase III trial of TH-302 for the treatment of pancreatic cancer. The study will be conducted by Germany's Merck, Threshold's partner in the development of TH-302. (PR) Comment! [Healthcare, On the Move]
Friday, April 20, 2012, 6:54 AM Merck KGaA (MKGAF.PK) CEO Karl-Ludwig Kley says the German pharmaceutical company will have to slash costs and cut staffing to stay competitive. During the savings initiative, Merck plans to hold back on making any major acquisitions in the space. 1 Comment [Global & FX, Healthcare]
Wednesday, April 11, 2012, 7:48 AM Threshold Pharmaceuticals (THLD) earns a $20M milestone payment from Merck KGaA (MKGAF.PK). The payment was tied to performance of its TH-302 pancreatic cancer treatment candidate in a Phase 2 trial. Comment! [Healthcare]
Tuesday, March 6, 2012, 6:52 AM Shares of Oncothyreon (ONTY) fall 32.4% in premarket trading after Merck KgaA (MKGAF.PK) announces that studies on the experimental lung-cancer drug Stimuvax won't be completed until next year. Stimuvax is being developed by Merck KGaA under a license agreement with Oncothyreon. Comment! [Healthcare, On the Move]
Friday, February 3, 2012, 7:39 AM Shares of Threshold Pharmaceuticals (THLD) skyrocket, up 62.1%, after the biotech firm announces that it landed a deal with Merck KGaA (MKGAF.PK) to co-develop and commercialize its TH-302 cancer treatment drug. Props to M. E. Garza who nailed this call in December. Comment! [On the Move, Healthcare]
Wednesday, July 27, 2011, 3:09 AM Merck KGaA (MKGAF.PK) reports a Q2 net EPS loss of €0.40 ($0.58), vs. profit of €0.84 a year earlier. Revenue +16% to €2.56B. For 2011, Merck expects operating profit of about €1B, below guidance given in April, due to one-time adjustments. 2 Comments [Earnings, Healthcare]

MKGAF.PK Merck Kgaa Dm 5

MKGAF.PK

Merck Kgaa Dm 5